JOHNSON & JOHNSON Annual Report, Year Ended Jan 3, 2016

Johnson & Johnson's 2016 10-K filing reveals a year of transition, with total sales decreasing by 5.7% to $70.1 billion, primarily due to unfavorable currency impacts (7.5%) and the introduction of competitive products in the Hepatitis C market. The company continues to invest heavily in research and development, allocating $9.0 billion (12.9% of sales) to innovation across its three segments: Consumer, Pharmaceutical, and Medical Devices. The Pharmaceutical segment experienced operational growth, largely driven by strong performance in Immunology and Oncology, though impacted by Hepatitis C product competition. The Medical Devices segment saw a decline in sales, partly due to divestitures of the Cordis and Ortho-Clinical Diagnostics businesses, but showed operational resilience in key areas like Orthopaedics and Surgery. The company also announced a significant restructuring initiative within its Medical Devices segment, aiming for annualized pre-tax cost savings of $800 million to $1.0 billion. Financially, the company generated robust operating cash flow of $19.3 billion. Despite a decrease in earnings before taxes due to factors like currency headwinds and restructuring charges, Johnson & Johnson demonstrated a strong commitment to shareholders by increasing its dividend for the 53rd consecutive year and continuing its share repurchase program. The company's financial position remains strong, with significant cash reserves and a manageable debt-to-capital ratio, positioning it to navigate market challenges and invest in future growth.